No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
diabetes
drug-drug interaction
glimepiride
henagliflozin
pharmacokinetics
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
05
03
2022
received:
07
12
2021
accepted:
16
03
2022
pubmed:
2
4
2022
medline:
25
8
2022
entrez:
1
4
2022
Statut:
ppublish
Résumé
Henagliflozin is a novel selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with similar inhibitory effect to ertugliflozin. Glimepiride is widely used to treat type 2 diabetes mellitus (T2DM) with few cardiovascular side effects. In the present study, we aimed at evaluating the pharmacokinetic (PK) interactions between henagliflozin and glimepiride. An open-label, single-centre, single-arm, 3-period, 3-treatment, self-control study was conducted in twelve healthy Chinese male subjects. During each study period, subjects received a single oral dose of glimepiride 2 mg, multiple oral doses of henagliflozin 10 mg or a combination of the two drugs. Serial blood samples were collected 24 h post-dosing for PK analyses. Finger-tip blood glucose was also tested for safety evaluation. Co-administration of henagliflozin with glimepiride did not affect their plasma PK profiles. For henagliflozin, the 90% confidence intervals for the geometric mean ratio (GMR) for the maximum plasma concentrations at steady-state (C Multiple doses of henagliflozin did not exert a significant change on glimepiride PK profiles and a single dose of glimepiride had little effect on henagliflozin blood concentration. Thus, henagliflozin can be co-administered with glimepiride without dose adjustment of either drug.
Substances chimiques
Blood Glucose
0
Bridged Bicyclo Compounds, Heterocyclic
0
Sodium-Glucose Transporter 2 Inhibitors
0
Sulfonylurea Compounds
0
henagliflozin
21P2M98388
glimepiride
6KY687524K
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1225-1231Subventions
Organisme : Jiang Su Heng Rui Medicine Co, Ltd, P.R. China
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Genco RJ, Graziani F, Hasturk H. Effects of periodontal disease on glycemic control, complications, and incidence of diabetes mellitus. Periodontol 2000. 2020;83(1):59-65.
International Diabetes Federation. IDF Diabetes Atlas (9th ed.). 2019. Accessed Jun 25, 2021. Available at: https://www.diabetesatlas.org
Magliano DJ, Sacre JW, Harding JL, et al. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020;16(6):321-331.
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61:2079-2086.
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):556-577.
Wang LP, Wu CY, Shen L, et al. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males. Xenobiotica. 2016;46(8):703-708.
Yong X, Wen A, Liu X, et al. Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose Co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus. Clin Drug Investig. 2016;36(3):195-202.
Zhang YF, Liu YM, Yu C, et al. Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single- and multiple-dose administration. Clin Ther. 2021;43(2):396-409.
Madsen KS, Kähler P, Kähler LKA, et al. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;18:4(4):CD012368.
Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463-472.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(Suppl. 1):S73-S85.
Kalra S, Bahendeka S, Sahay R, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force. Indian J Endocrinol Metab. 2018;22(1):132-157.
Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6(2):225-235.
Tian L, Huang YL, Hua L, et al. Pharmacokinetic studies of glimepiride and its hydroxy-metabolite in healthy volunteers. Chinese J Clin Pharmacol Ther. 2006;08:868-872.
Wang R, Fang Y, Wang ZX, et al. Phase Ⅰ clinical trial on tolerability of glimepiride in single oral dose. Chinese Journal of New Drugs. 2001;08:609-612.
Chen ZD, Chen Q, Zhu YT, et al. Effects of food on the pharmacokinetic properties and mass balance of henagliflozin in healthy male volunteers. Clin Ther. 2021;S0149-2918(21):00252-256.
Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. J Diabetes Res Clin Metab. 2012;1(1):14.
Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14(10):937-943.
Sasaki T, Seino Y, Fukatsu A, et al. Absence of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and various oral antidiabetic drugs in healthy Japanese Males. Adv Ther. 2015;32(5):404-417.
Kasahara N, Fukase H, Ohba Y, et al. A pharmacokinetic/pharmacodynamic drug-drug interaction study of tofogliflozin (a new SGLT2 Inhibitor) and selected anti-type 2 diabetes mellitus drugs. Drug Res. 2015;66(02):74-81.
Dawra VK, Cutler DL, Zhou S, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314-325.
Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2015;13(1):47-54.
Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-1225.
Li J, Shao YH, Wang XG, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocr J. 2018;65(3):335-344.